Breast Cancer Risk Factors and Menopausal Hormone Therapy
Author Information
Author(s): Lena U. Rosenberg, Cecilia Magnusson, Emma Lindström, Sara Wedrén, Per Hall, Paul W. Dickman
Primary Institution: Karolinska Institutet
Hypothesis
What is the relationship between menopausal hormone therapy and the risk of different histological subtypes of breast cancer?
Conclusion
Menopausal hormone therapy was associated with increased risks for breast cancer of both ductal and lobular subtype, with medium potency estrogen-progestin therapy being more strongly associated with lobular compared to ductal cancer.
Supporting Evidence
- Women using medium potency estrogen-progestin for ≥5 years had an OR of 6.5 for tubular cancer.
- Low potency oral estrogen was associated with an increased risk for lobular cancer.
- Recent alcohol consumption of >10 g/day was associated with increased risk only for tubular cancer.
Takeaway
Using hormone therapy during menopause can increase the chances of getting certain types of breast cancer, especially lobular cancer.
Methodology
A population-based case-control study comparing women diagnosed with invasive breast cancer to age-frequency matched controls.
Potential Biases
Potential misclassification of hormone therapy use due to self-reporting.
Limitations
The study may have small sample sizes for certain cancer subtypes, and recall bias could affect the accuracy of self-reported hormone therapy use.
Participant Demographics
Women aged 50 to 74 years diagnosed with invasive breast cancer in Sweden.
Statistical Information
Confidence Interval
95% CI 3.2–9.7 for lobular cancer; 95% CI 2.8–14.9 for tubular cancer; 95% CI 1.6–3.3 for ductal cancer.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website